Avience Biomedicals SME IPO GMP Today and Subject 2 Price
Avience Biomedicals SME IPO Grey Market Premium (GMP) today stands at ₹ 85, indicating strong potential for listing gains and robust investor interest. The Kostak rate is currently not available, while the Subject to Sauda price is quoted at currently not available. On 19 June 2026, the IPO GMP recorded a high of ₹85 and a low of ₹63 on 16 June 2026, signaling high market confidence. You can check the day-wise GMP trend below to track price movement and investor sentiment over time.
Avience Biomedicals SME IPO is scheduled to open for subscription on June 18, 2026. The public issue aims to raise around ₹30.24 Cr. and is offered in a price band of ₹196 to ₹208 per share, with a market lot of 600 shares. Investors are closely watching subscription data and grey market trends ahead of the listing.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 19 Jun 2026 | ₹ 85 | 40.9% | ₹ 0 | ₹ 0 | |
| 18 Jun 2026 | ₹ 85 | 40.9% | ₹ 0 | ₹ 0 | |
| 17 Jun 2026 | ₹ 75 | 36.1% | ₹ 0 | ₹ 0 | |
| 16 Jun 2026 | ₹ 63 | 30.3% | ₹ 0 | ₹ 0 | |
| 15 Jun 2026 | ₹ 70 | 33.7% | ₹ 0 | ₹ 0 |
Avience Biomedicals SME IPO Dates
| Event | Date |
|---|---|
| Open Date | 18 Jun, 2026 |
| Close Date | 22 Jun, 2026 |
| Allotment Date | 23 Jun, 2026 |
| Refund Date | TBA |
| Credit to Demat | TBA |
| Listing Date | 25 Jun, 2026 |
Avience Biomedicals SME IPO Expected Listing Price
| Basis | Value |
|---|---|
| Issue Price (Upper Band) | ₹208 |
| Current GMP | ₹ 85 |
| GMP-Based Listing Estimate | ₹293 (+40.9%) |
| Listing Date | 25 Jun, 2026 |
Disclaimer: The listing price estimate above is based purely on the current grey market premium (GMP) and is not a guaranteed prediction. GMP is an unofficial, unregulated indicator and can change significantly in the 24–48 hours before listing. Do not make investment decisions based solely on GMP.
Is Avience Biomedicals SME IPO GMP Reliable?
Grey market premium for Avience Biomedicals SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Avience Biomedicals SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Avience Biomedicals SME IPO IPO Kostak Rate Explained
The Kostak rate for Avience Biomedicals SME IPO is currently not active. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price has not been quoted yet. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Avience Biomedicals SME IPO
Frequently Asked Questions about Avience Biomedicals SME IPO
What is the GMP of Avience Biomedicals SME IPO?
The current Grey Market Premium (GMP) of Avience Biomedicals SME IPO is ₹ 85.
What is the Kostak Price of Avience Biomedicals SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Avience Biomedicals SME IPO is currently not available.
What is the Subject to Sauda Price of Avience Biomedicals SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What is the expected listing price of Avience Biomedicals SME IPO based on GMP?
Based on the current GMP of ₹ 85, Avience Biomedicals SME IPO is expected to list around ₹293 — approximately +40.9% above the issue price of ₹208. Grey market prices can shift before listing — treat this as an estimate only.
Is the GMP of Avience Biomedicals SME IPO increasing or decreasing?
The GMP of Avience Biomedicals SME IPO is currently stable. Track the day-wise GMP table above for the latest movement.
Explore Avience Biomedicals SME IPO Further
For a complete picture before making your investment decision, explore these resources:
Discussion 0
No comments yet
Be the first to share your thoughts!